Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are ...

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...

CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically ...

The company believes its lead drug, which is currently in mid-stage testing, could address limitations of other therapies for ...

The deal is the third acquisition since May involving a drug that could reverse liver scarring in people with metabolic dysfunction-associated steatohepatitis.

Libtayo’s latest approval for a type of skin cancer should boost future sales, according to one analyst, but doesn’t have the ...